JACC:长链非编码RNA可调控心脏再生能力

2018-07-31 MedSci MedSci原创

成年哺乳动物的心脏由于缺乏有丝分裂能力而不能再生。本研究的目的旨在评估长链非编码RNA(lncRNAs)在成年心脏损伤后再生中的作用及机制。本研究发现一种lncRNA-CAREL在失去再生能力的新生小鼠(P7)心肌中表达量升高,通过Myh6介导的心肌特异性过表达lncRNA-CAREL转基因小鼠模型,发现该转基因小鼠心肌损伤后心肌细胞的分裂和增殖能力下降,通过病毒在体内敲降lncRNA-CAREL

成年哺乳动物的心脏由于缺乏有丝分裂能力而不能再生。本研究的目的旨在评估长链非编码RNA(lncRNAs)在成年心脏损伤后再生中的作用及机制。

本研究发现一种lncRNA-CAREL在失去再生能力的新生小鼠(P7)心肌中表达量升高,通过Myh6介导的心肌特异性过表达lncRNA-CAREL转基因小鼠模型,发现该转基因小鼠心肌损伤后心肌细胞的分裂和增殖能力下降,通过病毒在体内敲降lncRNA-CAREL却能促进心脏的再生能力,并提高新生和成年小鼠的心脏功能。lncRNA-CAREL作为miR-296的竞争性内源核苷酸,抑制Trp53inp1和Itm2a基因的表达。过表达miR-296可以促进心肌损伤后的心脏再生,lncRNA-CAREL转基因小鼠下降的心脏再生能力可被miR-296补救。另外,包含lncRNA-CARE保守结构域的短核酸片段也可降低人类干细胞诱导的心肌细胞的增殖再生能力。

本研究结果显示,长链非编码RNA-CAREL作为miR-296的竞争性内源核苷酸可以调控小鼠心脏损伤后心脏的再生能力。

原始出处

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854109, encodeId=b0e3185410919, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 15 13:40:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037676, encodeId=2ebd203e67656, content=<a href='/topic/show?id=636d3068e52' target=_blank style='color:#2F92EE;'>#再生能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30687, encryptionId=636d3068e52, topicName=再生能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Oct 14 04:40:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743474, encodeId=2e0a1e4347432, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Nov 23 15:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325915, encodeId=395f1325915ef, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485823, encodeId=cf39148582339, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584710, encodeId=e9ce1584e10fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335473, encodeId=78103354e3d9, content=lnkRNA是现在的研究热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Wed Aug 01 07:43:17 CST 2018, time=2018-08-01, status=1, ipAttribution=)]
    2019-03-15 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854109, encodeId=b0e3185410919, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 15 13:40:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037676, encodeId=2ebd203e67656, content=<a href='/topic/show?id=636d3068e52' target=_blank style='color:#2F92EE;'>#再生能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30687, encryptionId=636d3068e52, topicName=再生能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Oct 14 04:40:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743474, encodeId=2e0a1e4347432, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Nov 23 15:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325915, encodeId=395f1325915ef, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485823, encodeId=cf39148582339, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584710, encodeId=e9ce1584e10fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335473, encodeId=78103354e3d9, content=lnkRNA是现在的研究热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Wed Aug 01 07:43:17 CST 2018, time=2018-08-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854109, encodeId=b0e3185410919, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 15 13:40:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037676, encodeId=2ebd203e67656, content=<a href='/topic/show?id=636d3068e52' target=_blank style='color:#2F92EE;'>#再生能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30687, encryptionId=636d3068e52, topicName=再生能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Oct 14 04:40:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743474, encodeId=2e0a1e4347432, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Nov 23 15:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325915, encodeId=395f1325915ef, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485823, encodeId=cf39148582339, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584710, encodeId=e9ce1584e10fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335473, encodeId=78103354e3d9, content=lnkRNA是现在的研究热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Wed Aug 01 07:43:17 CST 2018, time=2018-08-01, status=1, ipAttribution=)]
    2018-11-23 d830384
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854109, encodeId=b0e3185410919, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 15 13:40:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037676, encodeId=2ebd203e67656, content=<a href='/topic/show?id=636d3068e52' target=_blank style='color:#2F92EE;'>#再生能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30687, encryptionId=636d3068e52, topicName=再生能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Oct 14 04:40:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743474, encodeId=2e0a1e4347432, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Nov 23 15:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325915, encodeId=395f1325915ef, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485823, encodeId=cf39148582339, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584710, encodeId=e9ce1584e10fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335473, encodeId=78103354e3d9, content=lnkRNA是现在的研究热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Wed Aug 01 07:43:17 CST 2018, time=2018-08-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854109, encodeId=b0e3185410919, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 15 13:40:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037676, encodeId=2ebd203e67656, content=<a href='/topic/show?id=636d3068e52' target=_blank style='color:#2F92EE;'>#再生能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30687, encryptionId=636d3068e52, topicName=再生能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Oct 14 04:40:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743474, encodeId=2e0a1e4347432, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Nov 23 15:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325915, encodeId=395f1325915ef, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485823, encodeId=cf39148582339, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584710, encodeId=e9ce1584e10fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335473, encodeId=78103354e3d9, content=lnkRNA是现在的研究热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Wed Aug 01 07:43:17 CST 2018, time=2018-08-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1854109, encodeId=b0e3185410919, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 15 13:40:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037676, encodeId=2ebd203e67656, content=<a href='/topic/show?id=636d3068e52' target=_blank style='color:#2F92EE;'>#再生能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30687, encryptionId=636d3068e52, topicName=再生能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Oct 14 04:40:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743474, encodeId=2e0a1e4347432, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Nov 23 15:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325915, encodeId=395f1325915ef, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485823, encodeId=cf39148582339, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584710, encodeId=e9ce1584e10fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335473, encodeId=78103354e3d9, content=lnkRNA是现在的研究热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Wed Aug 01 07:43:17 CST 2018, time=2018-08-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1854109, encodeId=b0e3185410919, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 15 13:40:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2037676, encodeId=2ebd203e67656, content=<a href='/topic/show?id=636d3068e52' target=_blank style='color:#2F92EE;'>#再生能力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30687, encryptionId=636d3068e52, topicName=再生能力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Oct 14 04:40:00 CST 2018, time=2018-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743474, encodeId=2e0a1e4347432, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Fri Nov 23 15:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325915, encodeId=395f1325915ef, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485823, encodeId=cf39148582339, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584710, encodeId=e9ce1584e10fa, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Thu Aug 02 05:40:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335473, encodeId=78103354e3d9, content=lnkRNA是现在的研究热点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Wed Aug 01 07:43:17 CST 2018, time=2018-08-01, status=1, ipAttribution=)]
    2018-08-01 liumin1987

    lnkRNA是现在的研究热点。

    0

相关资讯

JACC:蛋白酶抑制剂会增加HIV伴心衰患者死亡率

HIV患者的心衰发生风险会增加。蛋白酶抑制剂(PIs)与不良的心脏重塑和血管事件相关,但PIs在HIV伴心衰的患者中的使用情况尚不清楚。本研究的目的旨在比较HIV伴心衰患者接受包含PIs的治疗和不包含PIs(NPI)治疗的临床特征的差异。本研究纳入了394名接受抗逆转录病毒治疗的因心衰住院的HIV患者(平均年龄60 ± 9.5岁,女性占47%,CD4计数292 ± 206 个/mm3),其中145

JACC:低剂量利伐沙班在亚洲房颤人群的安全性和有效性研究

低剂量利伐沙班(10mg/天)在亚洲房颤患者中已被广泛使用,但其有效性尚缺乏全面的评估。在亚洲人群中,低剂量利伐沙班是否与标准剂量利伐沙班一样有效尚不清楚。本研究的 目的旨在评估亚洲房颤患者服用标准剂量利伐沙班(15或20mg/天)和低剂量利伐沙班(10mg/天)的安全性和有效性。本研究纳入了健康数据库中的6558名亚洲房颤患者,其中2373名和4185名患者分别接受了低剂量和标准剂量的利伐沙班治

Arter Throm Vas Bio:中老年阿姨注意了!化验单上这一指标可能并不能说明你的心血管

情人眼里出西施,人们总是带着主观性定义“好”和“坏”,胆固醇也不例外。通常,医生以定期监测“好胆固醇”(高密度脂蛋白)和“坏胆固醇”(低密度脂蛋白)的水平作为评估心血管健康的依据。但近日匹兹堡大学提供的新证据却驳斥了这一标准:特定类型的血液胆固醇测量可能不会降低老年妇女患心血管疾病的风险。

盘点:JACC7月第4期研究一览

1. 仅少数心衰患者的药物和剂量使用符合指南推荐标准DOI: 10.1016/j.jacc.2018.04.070http://www.onlinejacc.org/content/72/4指南对于射血分数减少型心衰(HFrEF)患者,强烈推荐接受药物联合治疗以改善预后,然而,对于门诊病人药物的使用和剂量的控制尚不清楚。CHAMP-HF数据库纳入了美国至少接受有一种心衰药物治疗的慢性心衰门诊患

JAHA:健康生活方式对降脂降压药的影响

目前,对于降血脂药物和降压药物的效果是否会受健康的生活方式影响尚不清楚。本研究的目的旨在评估HOPE‐3临床试验中的健康的生活方式对这两种药物治疗效果的影响。在该临床试验中,记录了12521例具有心血管疾病发生风险的参与者的4种健康生活方式(不吸烟,体育锻炼,理想的体重和健康的饮食),并随机分成了瑞舒伐他汀组、坎地沙坦/氢氯噻嗪组、两种药物的组合或安慰剂组。平均随访时间是5.6年。分析结果显示,有

JACC:Etripamil 鼻喷雾剂治疗阵发性室上速安全有效

目前,还没有能快速终止阵发性室上速的注射药物。本研究的目的旨在评估etripamil鼻喷雾剂(一种短效钙离子阻断剂)治疗阵发性室上速(SVT)的安全性和有效性。本研究的研究对象是因SVT行电生理检查的患者,SVT持续时间在5min以上的患者接受了安慰剂或不同剂量的etripamil鼻喷雾剂治疗。本研究的主要终点事件是药物治疗15min内的SVT转化率,次要终点事件包括转化所需的时间和不良反应事件。